Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study

Journal of Alzheimer's Disease

Volumn 50, Issue 3, 2016, Pages 887-894

  Chatterjee, Pratishtha ^a,b,c,d   Lim, Wei L F ^b,c,d   Shui, Guanghou ^e   Gupta, Veer B ^b,c,d   James, Ian ^f   Fagan, Anne M ^g   Xiong, Chengjie ^g,h   Sohrabi, Hamid R ^a,b,c,d   Taddei, Kevin ^a,b,d   Brown, Belinda M ^a,b,d   Benzinger, Tammie ^g,h   Masters, Colin ⁱ   Snowden, Stuart G ^j   Wenk, Marcus R ^k   Bateman, Randall J ^g   Morris, John C ^g   Martins, Ralph N ^a,b,c,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b McCusker Alzheimer's Research foundation   (Australia)

^c CRC for Mental Health   (Australia)

^d EDITH COWAN UNIVERSITY   (Australia)

^e INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^f MURDOCH UNIVERSITY   (Australia)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j KING'S COLLEGE LONDON   (United Kingdom)

^k NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

more..

Author keywords

Alzheimer's disease; biomarkers; familial Alzheimer's disease; phospholipids; sphingolipids

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CERAMIDE; CHOLINE; ETHANOLAMINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PLASMALOGEN; PRESENILIN 1; SPHINGOLIPID; TAU PROTEIN; THREONINE;

ADULT; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PHOSPHOLIPID BLOOD LEVEL; PILOT STUDY; PRIORITY JOURNAL; SPHINGOLIPID METABOLISM; ALZHEIMER DISEASE; BLOOD; GENETICS; MIDDLE AGED; MUTATION; STATISTICAL MODEL;

ADULT; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MUTATION; PHOSPHOLIPIDS; PILOT PROJECTS; PRESENILIN-1; SPHINGOLIPIDS;

EID: 84957916683     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150948     Document Type: Article

References (35)

1. MielkeMM, LyketsosCG (2006) Lipids and the pathogenesis of Alzheimer's disease: Is there a link? Int Rev Psychiatry 18, 173-186.
2. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 89, 1671-1675.
3. Soderberg M, Edlund C, Alafuzoff I, Kristensson K, Dallner G (1992) Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type. J Neurochem 59, 1646-1653.
4. Han X, Holtzman DM, McKeel DW Jr (2001) Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77, 1168-1180.
5. Han X, D MH, McKeel DW Jr, Kelley J, Morris JC (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: Potential role in disease pathogenesis. J Neurochem 82, 809-818.
6. Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, Wenk MR, Shui G, Di Paolo G (2012) Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 287, 2678-2688.
7. Wood PL (2012) Lipidomics of Alzheimer's disease: Current status. Alzheimers Res Ther 4, 5.
8. Whiley L, Sen A, Heaton J, Proitsi P, Garcia-Gomez D, Leung R, Smith N, Thambisetty M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Lovestone S, Legido-Quigley C, AddNeuroMed C (2014) Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging 35, 271-278.
9. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Macarthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20, 415-418.
10. Cui Y, Liu X, Wang M, Liu L, Sun X, Ma L, Xie W, Wang C, Tang S, Wang D, Wu Q (2014) Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatographyquadrupole time-of-flight mass spectrometry-based metabonomics. J Neuropathol Exp Neurol 73, 954-963.
11. Mielke MM, Haughey NJ, BandaruVV,Weinberg DD, Darby E, Zaidi N, Pavlik V, Doody RS, Lyketsos CG (2011) Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis 27, 259-269.
12. Mielke MM, Bandaru VV, Haughey NJ, Xia J, Fried LP, Yasar S, Albert M, Varma V, Harris G, Schneider EB, Rabins PV, Bandeen-Roche K, Lyketsos CG, Carlson MC (2012) Serum ceramides increase the risk of Alzheimer disease: The Women's Health and Aging Study II. Neurology 79, 633-641.
13. Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20, 154-159.
14. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape JA, De Strooper B, Muller U, Shen J, Hartmann T (2005) Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 7, 1118-1123.
15. Landman N, Jeong SY, Shin SY, Voronov SV, Serban G, Kang MS, Park MK, Di Paolo G, Chung S, Kim TW (2006) Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc Natl Acad Sci U S A 103, 19524-19529.
16. StillwellW,Wassall SR (2003) Docosahexaenoic acid: Membrane properties of a unique fatty acid. Chem Phys Lipids 126, 1-27.
17. Grimm MO, Ackermann R (2005) Transurethral resection of superficial bladder cancer: Technically safe, oncologically anything but perfect. J Urol 174, 2086-2087.
18. Farooqui AA, Horrocks LA (2006) Phospholipase A2-generated lipid mediators in the brain: The good, the bad, and the ugly. Neuroscientist 12, 245-260.
19. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M,Wood PL (2007) Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. J Lipid Res 48, 2485-2498.
20. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, Dominantly Inherited Alzheimer N (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
21. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ, Dominantly Inherited Alzheimer N (2014) Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis. Neurology 83, 253-260.
22. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, BucklesV, OliverA,Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
23. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414.
24. Lim WL, Lam SM, Shui G, Mondal A, Ong D, Duan X, Creegan R, Martins IJ, Sharman MJ, Taddei K, Verdile G, Wenk MR, Martins RN (2013) Effects of a high-fat, highcholesterol diet on brain lipid profiles in apolipoprotein E epsilon3 and epsilon4 knock-in mice. Neurobiol Aging 34, 2217-2224.
25. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37, 911-917.
26. Lam SM, Tong L, Duan X, Petznick A, Wenk MR, Shui G (2014) Extensive characterization of human tear fluid collected using different techniques unravels the presence of novel lipid amphiphiles. J Lipid Res 55, 289-298.
27. Folstein MF, Folstein SE, McHugh PR (1975) 'Mini-mental state'. A practical method for graDing the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
28. Han X, Gross RW (2005) Shotgun lipidomics: Electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev 24, 367-412.
29. Katsuki H, Okuda S (1995) Arachidonic acid as a neurotoxic and neurotrophic substance. Prog Neurobiol 46, 607-636.
30. Almeida T, Cunha RA, Ribeiro JA (1999) Facilitation by arachidonic acid of acetylcholine release from the rat hippocampus. Brain Res 826, 104-111.
31. Fonteh AN, Chiang J, Cipolla M, Hale J, Diallo F, Chirino A, Arakaki X, Harrington MG (2013) Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease. J Lipid Res 54, 2884-2897.
32. Gorgas K, Teigler A, Komljenovic D, Just WW (2006) The ether lipid-deficient mouse: Tracking down plasmalogen functions. Biochim Biophys Acta 1763, 1511-1526.
33. Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC (2010) Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 31, 17-24.
34. Mielke MM, Haughey NJ, Ratnam Bandaru VV, Schech S, Carrick R, Carlson MC, Mori S, Miller MI, Ceritoglu C, Brown T, Albert M, Lyketsos CG (2010) Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 6, 378-385.
35. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM (2009) Cerebrospinal fluid tau and ptau (181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1, 371-380.